{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:44:20Z","timestamp":1788252260267,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cbi.2025.111848","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T15:59:06Z","timestamp":1763827146000},"page":"111848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hybrid molecules with dual inhibition of acetylcholinesterase and tau hyperphosphorylation: design, inhibitory activity evaluation, apoptosis assessment, and mechanistic exploration"],"prefix":"10.1016","volume":"423","author":[{"given":"Qingfeng","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingnian","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-3301","authenticated-orcid":false,"given":"Ailing","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111848_bib1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2025.111848_bib2","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/alz.12901","article-title":"The worldwide costs of dementia in 2019","volume":"19","author":"Wimo","year":"2023","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.cbi.2025.111848_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13195-022-01055-y","article-title":"Perspectives and challenges in patient stratification in Alzheimer's disease","volume":"14","author":"Abdelnour","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.cbi.2025.111848_bib4","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","article-title":"Emerging diagnostics and therapeutics for Alzheimer disease","volume":"29","author":"Self","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cbi.2025.111848_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1570159X1203140511153200","article-title":"Multi-target directed drugs: a modern approach for design of new drugs for the treatment of Alzheimer's disease","volume":"12","author":"Dias","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.cbi.2025.111848_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1742-4658.2007.06238.x","article-title":"Amyloid-cholinesterase interactions. Implications for Alzheimer's disease","volume":"275","author":"Inestrosa","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.cbi.2025.111848_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2025.111497","article-title":"Cholinesterase-based inhibitors as multitarget small molecules for the therapy of Alzheimer's disease","volume":"413","author":"Marco-Contelles","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2025.111848_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/cb900264w","article-title":"Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy","volume":"5","author":"Zheng","year":"2010","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.cbi.2025.111848_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acs.jmedchem.5b01119","article-title":"Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: design, synthesis, biological evaluation, and X-ray crystallography","volume":"59","author":"Zha","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1021\/acsmedchemlett.5b00483","article-title":"Design, synthesis, and evaluation of donepezil-like compounds as AChE and BACE-1 inhibitors","volume":"7","author":"Costanzo","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.cbi.2025.111848_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114305","article-title":"Novel inhibitors of AChE and A\u03b2 aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease","volume":"235","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ejmech.2019.07.051","article-title":"A novel class of multitarget anti-alzheimer benzohomoadamantane\u2013chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors","volume":"180","author":"P\u00e9rez-Areales","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/acschemneuro.8b00376","article-title":"Design, synthesis, and biological evaluation of dual-target inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 9A (PDE9A) for the treatment of alzheimer's disease","volume":"10","author":"Hu","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.cbi.2025.111848_bib14","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1021\/acs.jmedchem.1c00160","article-title":"Discovery of novel tacrine-pyrimidone hybrids as potent dual AChE\/GSK-3 inhibitors for the treatment of Alzheimer's disease","volume":"64","author":"Yao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib15","volume":"223","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103487","article-title":"Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies","volume":"28","author":"Moore","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cbi.2025.111848_bib17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","article-title":"Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer's disease? From preclinical studies to the clinical trials","volume":"28","author":"Basheer","year":"2023","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.cbi.2025.111848_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","article-title":"Tau and neurodegenerative disease: the story so far","volume":"12","author":"Iqbal","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cbi.2025.111848_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.590896","article-title":"New insights into drug discovery targeting Tau protein","volume":"13","author":"Soeda","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.cbi.2025.111848_bib20","article-title":"Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer's disease and cognitive functions","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2025.111848_bib21","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1007\/s00044-014-0931-2","article-title":"Design and synthesis of tacrine-phenothiazine hybrids as multitarget drugs for Alzheimer's disease","volume":"23","author":"Hui","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.cbi.2025.111848_bib22","unstructured":"A.L. Hui, C.S. Gan, W.C. Zhang, Y. Dai, J.H. Wang, Z.Y. Wu, Heterodimers with Indanone and Dibenzoazepine as Parent Nuclei, Their Hydrochlorides, Preparation Method and Application. Chinese Invention Patent Number ZL202210429089.8."},{"key":"10.1016\/j.cbi.2025.111848_bib23","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1021\/acs.jmedchem.0c02254","article-title":"Discovery of novel benzothiazepinones as irreversible covalent glycogen synthase kinase 3\u03b2 inhibitors for the treatment of acute promyelocytic leukemia","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111848_bib25","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/alz.12453","article-title":"A critical appraisal of tau-targeting therapies for primary and secondary tauopathies","volume":"18","author":"Imbimbo","year":"2022","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.cbi.2025.111848_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14283\/jpad.2022.63","article-title":"Oral tau aggregation inhibitor for Alzheimer's disease: design, progress and basis for selection of the 16 mg\/day dose in a phase 3, randomized, placebo-controlled trial of hydromethylthionine mesylate","volume":"9","author":"Wischik","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.cbi.2025.111848_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3233\/JAD-231007","article-title":"Quetiapine oral solution in alzheimer's disease: efficacy and dosage insights from a real-world retrospective study","volume":"97","author":"Li","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cbi.2025.111848_bib28","first-page":"10","article-title":"Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer's disease with behavioral and psychological symptoms of dementia, and their effects on vascular endothelial growth factors","volume":"21","author":"Yang","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cbi.2025.111848_bib29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11033-024-09558-7","article-title":"Quetiapine attenuates cadmium neurotoxicity by suppressing oxidative stress, inflammation, and pyroptosis","volume":"51","author":"Althagafy","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.cbi.2025.111848_bib30","first-page":"1688","article-title":"Repurposing diltiazem for its neuroprotective anti-dementia role against intra-cerebroventricular streptozotocin-induced sporadic Alzheimer's disease-type rat model","volume":"13","author":"Alluri","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.cbi.2025.111848_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejmech.2012.09.021","article-title":"Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3\u03b2 (GSK-3\u03b2)","volume":"61","author":"Zhang","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0957-4166(02)00833-9","article-title":"Synthesis of enantiopure angularly condensed [2.2]paracyclophanes containing five-membered rings","volume":"14","author":"Minuti","year":"2003","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.cbi.2025.111848_bib33","unstructured":"A.L. Wang, S.H. Liao, D.P. Li, Y.S. Jin, Y.C. You, Process for Selective Bromination of Ketone Carbonyl Compounds with N-bromosuccinimide. Chinese Invention Patent Application Number CN201110308724.9."},{"key":"10.1016\/j.cbi.2025.111848_bib34","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.tetlet.2016.07.012","article-title":"An efficient one-pot procedure for the synthesis of 1,5-benzothiazepinones catalyzed by tetrabutylammonium fluoride (TBAF)","volume":"57","author":"Zhang","year":"2016","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.cbi.2025.111848_bib35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1006981228331","article-title":"Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities","volume":"19","author":"Ekinci","year":"1999","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.cbi.2025.111848_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1196\/annals.1347.016","article-title":"Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease","volume":"1052","author":"Alvarez-de-la-Rosa","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.cbi.2025.111848_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2010.04.074","article-title":"Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner","volume":"1345","author":"Zhang","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.cbi.2025.111848_bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/978-981-32-9358-8_29","article-title":"Cerebrospinal fluid and plasma tau as a biomarker for brain tauopathy","volume":"1184","author":"Shoji","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.cbi.2025.111848_bib39","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.cbi.2025.111848_bib40","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1212\/01.wnl.0000242732.06714.0f","article-title":"Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury","volume":"67","author":"Ost","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cbi.2025.111848_bib41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5507\/bp.2017.038","article-title":"Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation","volume":"161","author":"Fialova","year":"2017","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.cbi.2025.111848_bib42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10495-023-01848-y","article-title":"Apoptosis in Alzheimer's disease: insight into the signaling pathways and therapeutic avenues","volume":"28","author":"Kumari","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.cbi.2025.111848_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuint.2011.05.010","article-title":"Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3\u03b2","volume":"59","author":"Martin","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.cbi.2025.111848_bib44","first-page":"2597","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.cbi.2025.111848_bib45","series-title":"Apoptosis and Human Health: Understanding Mechanistic and Therapeutic Potential","article-title":"Apoptosis: oxidative stress and antioxidants","author":"Halder","year":"2024"},{"key":"10.1016\/j.cbi.2025.111848_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/352723","article-title":"The ambiguous relationship of oxidative stress, tau hyperphosphorylation, and autophagy dysfunction in Alzheimer's disease","volume":"2015","author":"Liu","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.cbi.2025.111848_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/151979","article-title":"Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?","volume":"2015","author":"Alavi Naini","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.cbi.2025.111848_bib48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.cbi.2025.111848_bib49","doi-asserted-by":"crossref","first-page":"34873","DOI":"10.1074\/jbc.M405131200","article-title":"Promotion of hyperphosphorylation by frontotemporal dementia tau mutations","volume":"279","author":"Alonso","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib50","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s11064-006-9205-9","article-title":"Regulation of phosphorylation of tau by protein kinases in rat brain","volume":"31","author":"Sengupta","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cbi.2025.111848_bib51","doi-asserted-by":"crossref","first-page":"30851","DOI":"10.1074\/jbc.M110.110957","article-title":"Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration","volume":"285","author":"Alonso","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0896-6273(93)90279-Z","article-title":"Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding","volume":"11","author":"Biernat","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.cbi.2025.111848_bib53","doi-asserted-by":"crossref","first-page":"24977","DOI":"10.1074\/jbc.M000808200","article-title":"Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly","volume":"275","author":"Evans","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111848_bib54","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3233\/JAD-170810","article-title":"Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer's disease","volume":"61","author":"Yang","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cbi.2025.111848_bib55","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/alz.12502","article-title":"Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease","volume":"18","author":"Stathas","year":"2022","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.cbi.2025.111848_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/neuro.02.002.2009","article-title":"Crosstalk between Cdk5 and GSK3\u03b2: implications for Alzheimer's disease","volume":"2","author":"Engmann","year":"2009","journal-title":"Front. Mol. Neurosci."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725004788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725004788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:04:53Z","timestamp":1773849893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279725004788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S0009279725004788"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111848","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid molecules with dual inhibition of acetylcholinesterase and tau hyperphosphorylation: design, inhibitory activity evaluation, apoptosis assessment, and mechanistic exploration","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111848"}}